These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27058174)

  • 1. Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.
    Pfeuffer S; Ruck T; Kleinschnitz C; Wiendl H; Meuth SG
    Expert Rev Neurother; 2016 Jun; 16(6):689-700. PubMed ID: 27058174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020.
    Rolfes L; Pawlitzki M; Pfeuffer S; Huntemann N; Wiendl H; Ruck T; Meuth SG
    BioDrugs; 2020 Oct; 34(5):587-610. PubMed ID: 32785877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
    Ulzheimer JC; Meuth SG; Bittner S; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Aug; 24(4):249-74. PubMed ID: 20623991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
    Wiendl H; Hohlfeld R
    BioDrugs; 2002; 16(3):183-200. PubMed ID: 12102646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies.
    Meuth SG; Bittner S; Ulzheimer JC; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Oct; 24(5):317-30. PubMed ID: 20795753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?
    Krämer J; Wiendl H
    Neurotherapeutics; 2022 Apr; 19(3):785-807. PubMed ID: 35794296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.
    Huntemann N; Rolfes L; Pawlitzki M; Ruck T; Pfeuffer S; Wiendl H; Meuth SG
    Drugs; 2021 Jun; 81(9):1031-1063. PubMed ID: 34086251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H; Hohlfeld R
    Neurology; 2009 Mar; 72(11):1008-15. PubMed ID: 19289741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An update on the treatment options for multiple sclerosis].
    Niino M
    Brain Nerve; 2012 Dec; 64(12):1421-6. PubMed ID: 23209069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: clinical trial design 2019.
    Pardini M; Cutter G; Sormani MP
    Curr Opin Neurol; 2019 Jun; 32(3):358-364. PubMed ID: 30950845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis].
    Cazzato G; Antonello RM; Zorzon M; Torre P; Zivadinov R; Moretti R; Bragadin LM; De Masi R; Nasuelli D
    Recenti Prog Med; 1999 Oct; 90(10):538-44. PubMed ID: 10592740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment].
    Wiendl H; Neuhaus O; Kappos L; Hohlfeld R
    Nervenarzt; 2000 Aug; 71(8):597-610. PubMed ID: 10996910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE
    West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.